Dr Duncan Porter

  • Honorary Professor (Institute of Infection Immunity & Inflammation)

Publications

List by: Type | Date

Jump to: 2020 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 | 2010 | 2008 | 2004
Number of items: 29.

2020

Fragkoulis, G., Cavanagh, J. , Tindell, A., Derakhshan, M., Paterson, C., Porter, D., McInnes, I. B. and Siebert, S. (2020) Depression and anxiety in an Early Rheumatoid Arthritis inception cohort. Associations with demographic, socioeconomic and disease features. RMD Open, 6, e001376. (doi: 10.1136/rmdopen-2020-001376) (PMID:33127857)

Porter, D., Basu, N. and Siebert, S. (2020) Classification criteria: time for a rethink? Annals of the Rheumatic Diseases, 79(10), pp. 1264-1266. (doi: 10.1136/annrheumdis-2020-217769) (PMID:32699035)

Daly, R. et al. (2020) Changes in plasma itaconate elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites, 10(6), 241. (doi: 10.3390/metabo10060241) (PMID:32531990) (PMCID:PMC7344783)

2018

Tom, B. D.M., Symmons, D. and RA-MAP Consortium:, (2018) Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data. RMD Open, 4(2), e000721. (doi: 10.1136/rmdopen-2018-000721) (PMID:30487994) (PMCID:PMC6241979)

Fragoulis, G. E., Paterson, C., Gilmour, A., Derakhshan, M. H., McInnes, I. B. , Porter, D. and Siebert, S. (2018) Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. RMD Open, 4(2), e000739. (doi: 10.1136/rmdopen-2018-000739) (PMID:30402267) (PMCID:PMC6203094)

Taylor, J. C. et al. (2018) Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 18(4), pp. 528-538. (doi: 10.1038/s41397-018-0025-5) (PMID:29795407)

2017

Cope, A. P. et al. (2017) The RA-MAP Consortium: a working model for academia-industry collaboration. Nature Reviews Rheumatology, 14, pp. 53-60. (doi: 10.1038/nrrheum.2017.200) (PMID:29213124)

Robertson, J., Porter, D., Sattar, N. , Packard, C. J. , Caslake, M., McInnes, I. and McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. (doi: 10.1136/annrheumdis-2017-211708) (PMID:28916714)

Kurowska-Stolarska, M. et al. (2017) MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications, 8, 15877. (doi: 10.1038/ncomms15877) (PMID:28639625) (PMCID:PMC5489689)

McInnes, I. B. , Porter, D. and Siebert, S. (2017) Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? Arthritis and Rheumatology, 69(6), pp. 1131-1134. (doi: 10.1002/art.40082) (PMID:28245351)

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi: 10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

2016

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

Kronisch, C. et al. (2016) Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis inception cohort. Arthritis and Rheumatology, 68(7), pp. 1596-1602. (doi: 10.1002/art.39627) (PMID:26866516)

Porter, D. et al. (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 388(10041), pp. 239-247. (doi: 10.1016/S0140-6736(16)00380-9) (PMID:27197690)

Dale, J. et al. (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75(6), pp. 1043-1050. (doi: 10.1136/annrheumdis-2015-208941) (PMID:27026689)

Siebert, S. , Lyall, D. M. , Mackay, D. F. , Porter, D. and McInnes, I. B. (2016) Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. RMD Open, 2(1), e000267. (doi: 10.1136/rmdopen-2016-000267) (PMID:27403335) (PMCID:PMC4932291)

2014

Gibson, K. S., Woodburn, J., Porter, D. and Telfer, S. (2014) Functionally optimized orthoses for early rheumatoid arthritis foot disease: a study of mechanisms and patient experience. Arthritis Care and Research, 66(10), pp. 1456-1464. (doi: 10.1002/acr.22060)

Dale, J., Purves, D., McConnachie, A. , McInnes, I. and Porter, D. (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care and Research, 66(1), pp. 19-26. (doi: 10.1002/acr.22218)

Morgan, C.L., Emery, P., Porter, D., Reynolds, A., Young, A., Boyd, H., Poole, C.D. and Currie, C.J. (2014) Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology, 53(1), pp. 186-194. (doi: 10.1093/rheumatology/ket333)

Paul, L., Rafferty, D., Marshall-Mckenna, R. , Gill, J.M.R. , McInnes, I. , Porter, D. and Woodburn, J. (2014) Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 43(1), pp. 28-34. (doi: 10.3109/03009742.2013.802009)

Porter, D., Dale, J. and Sattar, N. (2014) How low to aim in rheumatoid arthritis? Learning from other disciplines. Annals of the Rheumatic Diseases, 73(3), pp. 480-482. (doi: 10.1136/annrheumdis-2013-204339)

Stalmach, A. , Johnsson, H., McInnes, I. B. , Husi, H., Klein, J., Dakna, M., Mullen, W. , Mischak, H. and Porter, D. (2014) Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE, 9(8), e104625. (doi: 10.1371/journal.pone.0104625) (PMID:25144639) (PMCID:PMC4140712)

2013

Porter, D.R. (2013) Step-up therapy remains an appropriate option. Annals of the Rheumatic Diseases, 72(5), e6. (doi: 10.1136/annrheumdis-2013-203242)

2012

Porter, D. (2012) Intensive management of early rheumatoid arthritis: the TICORA and TEAR studies. Clinical and Experimental Rheumatology, 30(Sup 73), S32-S34.

2010

Emery, P., Buch, M.H., Östör, A., Kirkham, B., Taylor, P., Estrach, C., Jenkinson, T., McInnes, I. and Porter, D. (2010) Time for treatment targets in rheumatoid arthritis. British Medical Journal, 341(c4170), p. 267. (doi: 10.1136/bmj.c4170)

Dale, J. and Porter, D. (2010) Optimising the strategy of care in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology, 24(4), pp. 443-455. (doi: 10.1016/j.berh.2009.11.009)

2008

Kielhorn, A., Porter, D., Diamantopoulos, A. and Lewis, G. (2008) UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Current Medical Research and Opinion, 24(9), pp. 2639-2650. (doi: 10.1185/03007990802321683)

Saunders, S.A., Capell, H.A., Stirling, A., Vallance, R., Kincaid, W., McMahon, A.D. and Porter, D.R. (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis and Rheumatism, 58(5), pp. 1310-1317. (doi: 10.1002/art.23449)

2004

Capell, H.A., Madhok, R., Hunter, J.A., Porter, D., Morrison, E., Larkin, J., Thomson, E.A., Hampson, R. and Poon, F.W. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases, 63(7), pp. 797-803. (doi: 10.1136/ard.2003.014050)

This list was generated on Tue Aug 3 23:39:17 2021 BST.
Jump to: Articles
Number of items: 29.

Articles

Fragkoulis, G., Cavanagh, J. , Tindell, A., Derakhshan, M., Paterson, C., Porter, D., McInnes, I. B. and Siebert, S. (2020) Depression and anxiety in an Early Rheumatoid Arthritis inception cohort. Associations with demographic, socioeconomic and disease features. RMD Open, 6, e001376. (doi: 10.1136/rmdopen-2020-001376) (PMID:33127857)

Porter, D., Basu, N. and Siebert, S. (2020) Classification criteria: time for a rethink? Annals of the Rheumatic Diseases, 79(10), pp. 1264-1266. (doi: 10.1136/annrheumdis-2020-217769) (PMID:32699035)

Daly, R. et al. (2020) Changes in plasma itaconate elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites, 10(6), 241. (doi: 10.3390/metabo10060241) (PMID:32531990) (PMCID:PMC7344783)

Tom, B. D.M., Symmons, D. and RA-MAP Consortium:, (2018) Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data. RMD Open, 4(2), e000721. (doi: 10.1136/rmdopen-2018-000721) (PMID:30487994) (PMCID:PMC6241979)

Fragoulis, G. E., Paterson, C., Gilmour, A., Derakhshan, M. H., McInnes, I. B. , Porter, D. and Siebert, S. (2018) Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. RMD Open, 4(2), e000739. (doi: 10.1136/rmdopen-2018-000739) (PMID:30402267) (PMCID:PMC6203094)

Taylor, J. C. et al. (2018) Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 18(4), pp. 528-538. (doi: 10.1038/s41397-018-0025-5) (PMID:29795407)

Cope, A. P. et al. (2017) The RA-MAP Consortium: a working model for academia-industry collaboration. Nature Reviews Rheumatology, 14, pp. 53-60. (doi: 10.1038/nrrheum.2017.200) (PMID:29213124)

Robertson, J., Porter, D., Sattar, N. , Packard, C. J. , Caslake, M., McInnes, I. and McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. (doi: 10.1136/annrheumdis-2017-211708) (PMID:28916714)

Kurowska-Stolarska, M. et al. (2017) MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications, 8, 15877. (doi: 10.1038/ncomms15877) (PMID:28639625) (PMCID:PMC5489689)

McInnes, I. B. , Porter, D. and Siebert, S. (2017) Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? Arthritis and Rheumatology, 69(6), pp. 1131-1134. (doi: 10.1002/art.40082) (PMID:28245351)

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi: 10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

Kronisch, C. et al. (2016) Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis inception cohort. Arthritis and Rheumatology, 68(7), pp. 1596-1602. (doi: 10.1002/art.39627) (PMID:26866516)

Porter, D. et al. (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 388(10041), pp. 239-247. (doi: 10.1016/S0140-6736(16)00380-9) (PMID:27197690)

Dale, J. et al. (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75(6), pp. 1043-1050. (doi: 10.1136/annrheumdis-2015-208941) (PMID:27026689)

Siebert, S. , Lyall, D. M. , Mackay, D. F. , Porter, D. and McInnes, I. B. (2016) Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. RMD Open, 2(1), e000267. (doi: 10.1136/rmdopen-2016-000267) (PMID:27403335) (PMCID:PMC4932291)

Gibson, K. S., Woodburn, J., Porter, D. and Telfer, S. (2014) Functionally optimized orthoses for early rheumatoid arthritis foot disease: a study of mechanisms and patient experience. Arthritis Care and Research, 66(10), pp. 1456-1464. (doi: 10.1002/acr.22060)

Dale, J., Purves, D., McConnachie, A. , McInnes, I. and Porter, D. (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care and Research, 66(1), pp. 19-26. (doi: 10.1002/acr.22218)

Morgan, C.L., Emery, P., Porter, D., Reynolds, A., Young, A., Boyd, H., Poole, C.D. and Currie, C.J. (2014) Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology, 53(1), pp. 186-194. (doi: 10.1093/rheumatology/ket333)

Paul, L., Rafferty, D., Marshall-Mckenna, R. , Gill, J.M.R. , McInnes, I. , Porter, D. and Woodburn, J. (2014) Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 43(1), pp. 28-34. (doi: 10.3109/03009742.2013.802009)

Porter, D., Dale, J. and Sattar, N. (2014) How low to aim in rheumatoid arthritis? Learning from other disciplines. Annals of the Rheumatic Diseases, 73(3), pp. 480-482. (doi: 10.1136/annrheumdis-2013-204339)

Stalmach, A. , Johnsson, H., McInnes, I. B. , Husi, H., Klein, J., Dakna, M., Mullen, W. , Mischak, H. and Porter, D. (2014) Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE, 9(8), e104625. (doi: 10.1371/journal.pone.0104625) (PMID:25144639) (PMCID:PMC4140712)

Porter, D.R. (2013) Step-up therapy remains an appropriate option. Annals of the Rheumatic Diseases, 72(5), e6. (doi: 10.1136/annrheumdis-2013-203242)

Porter, D. (2012) Intensive management of early rheumatoid arthritis: the TICORA and TEAR studies. Clinical and Experimental Rheumatology, 30(Sup 73), S32-S34.

Emery, P., Buch, M.H., Östör, A., Kirkham, B., Taylor, P., Estrach, C., Jenkinson, T., McInnes, I. and Porter, D. (2010) Time for treatment targets in rheumatoid arthritis. British Medical Journal, 341(c4170), p. 267. (doi: 10.1136/bmj.c4170)

Dale, J. and Porter, D. (2010) Optimising the strategy of care in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology, 24(4), pp. 443-455. (doi: 10.1016/j.berh.2009.11.009)

Kielhorn, A., Porter, D., Diamantopoulos, A. and Lewis, G. (2008) UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Current Medical Research and Opinion, 24(9), pp. 2639-2650. (doi: 10.1185/03007990802321683)

Saunders, S.A., Capell, H.A., Stirling, A., Vallance, R., Kincaid, W., McMahon, A.D. and Porter, D.R. (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis and Rheumatism, 58(5), pp. 1310-1317. (doi: 10.1002/art.23449)

Capell, H.A., Madhok, R., Hunter, J.A., Porter, D., Morrison, E., Larkin, J., Thomson, E.A., Hampson, R. and Poon, F.W. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases, 63(7), pp. 797-803. (doi: 10.1136/ard.2003.014050)

This list was generated on Tue Aug 3 23:39:17 2021 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • CiC Prognostic biomarkers in rheumatoid arthritis
    Medical Research Council
    2017 - 2017
     
  • Enabling Stratified Medicine in Early Rheumatoid Arthritis - predicting methotrexate (MTX) response and toxicity using an integrated polyomic approach (PROMISERA)
    Scottish Funding Council
    2014 - 2018
     
  • The use of polyomic analyses to direct biologic therapy in biologic-naive people with Rheumatoid Arthritis
    Chief Scientist Office
    2013 - 2015
     
  • Urine proteomics as biomarker for inflammatory arthritis
    Pfizer
    2013 - 2014
     
  • Leucocyte expression of the D6 chemokine decoy receptor in the pathogenesis of rheumatoid arthritis
    Arthritis Research UK
    2011 - 2013
     
  • Assessing the value and function of D6 as a novel prognostic marker of inflammatory diseases
    Chief Scientist Office
    2011 - 2013
     
  • ORBIT - Optimal management of RA patients who require Biologic Therapy
    Arthritis Research UK
    2010 - 2015
     
  • Tailoring therapy to individual patient needs - the challenge facing rheumatologists who treat patients with Early RA
    Scottish Executive Health Department
    2009 - 2012